Market Overview:
The global nedaplatin injection market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for nedaplatin as a chemotherapeutic agent, and technological advancements in the field of oncology. Based on type, the global nedaplatin injection market is segmented into 10mg, 50mg, and 100mg segments. The 10mg segment is expected to account for the largest share of the global nedaplatin injection market in 2018. This segment is also projected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. Based on application, the global nedaplatin injection market is divided into lung cancer, esophageal cancer bladder cancer,, testicular cancer,, ovarian cancer cervicalcancer,, and other applications segments.
Product Definition:
A chemotherapy drug used to treat ovarian cancer. It is a platinum-based drug.
10mg:
Nedaplatin is a platinum-based drug that is used in chemotherapy for cancer. It was first registered in Russia and India and later approved by the U.S. FDA for use as an anti-cancer drug under the trade name Taxotere (export only). Nedaplatin has been studied to be more effective than carboplatin with less adverse effects, which makes it suitable to be used as a second line of treatment after Carboplatin therapy.
50mg:
Nedaplatin is a chemotherapy drug and is used in the treatment of various cancers such as lumps or tumors in the breast, lung, bladder, mouth or throat. It works by killing cancer cells. Nedaplatin has also been shown to be effective against melanoma skin cancer when used with other drugs.
It's important to note that while nedaplatin may be an effective treatment for some types of cancers; it does not cure them.
Application Insights:
Lung cancer was the dominant application segment and accounted for a revenue share of around 40.0% in 2017 owing to the availability of several approved lung cancer drugs, such as Kadcyla, Xeloda, and Irinotecan. In addition, growing R&D activities pertaining to nedaplatin-based drugs for the treatment of non-small cell lung carcinoma is expected to fuel market growth over the forecast period.
Esophageal cancer is anticipated to be one of the fastest-growing applications due largely to increasing incidence rates globally coupled with rising demand for effective esophagealcancer treatments that are both cost-effective and highly efficient.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of key players, high adoption rate for novel therapeutics, and availability of approved drug products. The region is expected to maintain its dominance during the forecast period owing to factors such as favorable reimbursement scenario and increasing government funding for cancer research. Asia Pacific is anticipated to witness lucrative growth over the coming years due to rising healthcare spending by governments & private organizations, improving healthcare infrastructure & facilities along with growing awareness about early diagnosis among patients.
The market in Europe was valued at USD X million in 2017.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the nedaplatin injection market. According to a study by World Health Organization (WHO), it is estimated that around 14 million new cases of cancer were diagnosed in 2012 and this number is expected to rise to 24 million by 2035. This will create a high demand for nedaplatin injection as it is used for treatment of various types of cancers.
- Rising awareness about cancer treatments: There has been an increase in awareness about different types of cancers and their treatments in recent years. This has led to an increase in demand for nedaplatin injection as it offers an effective treatment option against various forms of cancer.
- Technological advancements in oncology therapies: There have been significant advancements made in oncology therapies over the past few years, which has led to increased adoption ratesof nedaplatin injection across the globe. With continuous technological advancements, this trend is likely to continue over the forecast period, thereby propellingthe growth prospectsfor thenedaplatininjection market .
- . Growing aging population: The global aging populationis growing at a rapid pace and this is expectedto drivethe demandforncedaplininjectionoverthe forecastperiodascanceris more prevalentamong elderly people than younger ones .This will create opportunities for players operating intheglobalnedaplininjectionmarket .
Scope Of The Report
Report Attributes
Report Details
Report Title
Nedaplatin Injection Market Research Report
By Type
10mg, 50mg, 100mg
By Application
Lung Cancer, Esophageal Cancer, Bladder Cancer, Testicular Cancer, Ovarian Cancer, Cervical Cancer, Other
By Companies
Qilu Pharma, Jilin Hengjin Pharmaceutical, Aosaikang Pharma, Simcere, Nichi-Iko Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
142
Number of Tables & Figures
100
Customization Available
Yes, the report can be customized as per your need.
Global Nedaplatin Injection Market Report Segments:
The global Nedaplatin Injection market is segmented on the basis of:
Types
10mg, 50mg, 100mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Cancer, Esophageal Cancer, Bladder Cancer, Testicular Cancer, Ovarian Cancer, Cervical Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Qilu Pharma
- Jilin Hengjin Pharmaceutical
- Aosaikang Pharma
- Simcere
- Nichi-Iko Pharmaceutical
Highlights of The Nedaplatin Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 10mg
- 50mg
- 100mg
- By Application:
- Lung Cancer
- Esophageal Cancer
- Bladder Cancer
- Testicular Cancer
- Ovarian Cancer
- Cervical Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nedaplatin Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nedaplatin is a chemotherapy drug that is used to treat cancer. It works by killing cancer cells.
Some of the major companies in the nedaplatin injection market are Qilu Pharma, Jilin Hengjin Pharmaceutical, Aosaikang Pharma, Simcere, Nichi-Iko Pharmaceutical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nedaplatin Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Nedaplatin Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Nedaplatin Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Nedaplatin Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Nedaplatin Injection Market Size & Forecast, 2020-2028
4.5.1 Nedaplatin Injection Market Size and Y-o-Y Growth
4.5.2 Nedaplatin Injection Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 10mg
5.2.2 50mg
5.2.3 100mg
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Lung Cancer
6.2.2 Esophageal Cancer
6.2.3 Bladder Cancer
6.2.4 Testicular Cancer
6.2.5 Ovarian Cancer
6.2.6 Cervical Cancer
6.2.7 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nedaplatin Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nedaplatin Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 10mg
9.6.2 50mg
9.6.3 100mg
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Lung Cancer
9.10.2 Esophageal Cancer
9.10.3 Bladder Cancer
9.10.4 Testicular Cancer
9.10.5 Ovarian Cancer
9.10.6 Cervical Cancer
9.10.7 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 10mg
10.6.2 50mg
10.6.3 100mg
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Lung Cancer
10.10.2 Esophageal Cancer
10.10.3 Bladder Cancer
10.10.4 Testicular Cancer
10.10.5 Ovarian Cancer
10.10.6 Cervical Cancer
10.10.7 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 10mg
11.6.2 50mg
11.6.3 100mg
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Lung Cancer
11.10.2 Esophageal Cancer
11.10.3 Bladder Cancer
11.10.4 Testicular Cancer
11.10.5 Ovarian Cancer
11.10.6 Cervical Cancer
11.10.7 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 10mg
12.6.2 50mg
12.6.3 100mg
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Lung Cancer
12.10.2 Esophageal Cancer
12.10.3 Bladder Cancer
12.10.4 Testicular Cancer
12.10.5 Ovarian Cancer
12.10.6 Cervical Cancer
12.10.7 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 10mg
13.6.2 50mg
13.6.3 100mg
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Lung Cancer
13.10.2 Esophageal Cancer
13.10.3 Bladder Cancer
13.10.4 Testicular Cancer
13.10.5 Ovarian Cancer
13.10.6 Cervical Cancer
13.10.7 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nedaplatin Injection Market: Competitive Dashboard
14.2 Global Nedaplatin Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Qilu Pharma
14.3.2 Jilin Hengjin Pharmaceutical
14.3.3 Aosaikang Pharma
14.3.4 Simcere
14.3.5 Nichi-Iko Pharmaceutical
